Cogent Biosciences (COGT) recently reported two closely linked FDA milestones for its lead cancer therapy, and those regulatory updates are now central to how many investors are thinking about the stock.

The FDA’s Breakthrough Therapy Designation and Real-Time Oncology Review decision arrived after a period of very strong market interest, with the share price at $37.28 and a 90 day share price return of 158.53%. The 1 year total shareholder return of 303.03% points to momentum that has been powerful rather than gradual, even though the 7 day share price return of 3.19% suggests some cooling after recent gains.

If Cogent’s cancer data has caught your attention, this can be a good moment to broaden the lens and look at other healthcare stocks that might fit a similar long term theme.

With the shares up more than 300% over the past year and trading at $37.28, the key question now is whether Cogent Biosciences is still undervalued after the FDA news or if the market is already pricing in future growth.

Preferred Price-to-Book Multiple of 29.2x: Is It Justified?

Cogent Biosciences is currently trading on a P/B of 29.2x, which is far above the US Biotechs industry average of 2.7x and the peer average of 5.1x. This means the market is attaching a very rich valuation multiple to the company at the last close of $37.28.

The P/B ratio compares the share price to the company’s book value per share, which is essentially its net assets on the balance sheet. For early stage biotech companies without meaningful revenue and with losses, investors often focus on assets, pipeline potential and future forecasts rather than current earnings. In these situations, P/B becomes one of the few usable yardsticks.

In Cogent’s case, a 29.2x P/B implies investors are paying a substantial premium to the value of its net assets, while the company reported a loss of $294.372m and makes less than $1m in revenue. Forecasts point to revenue growth of 52.3% per year and earnings growth of 57.17% per year with an expectation that the business becomes profitable in the next 3 years. This helps explain why some investors may be comfortable with a higher multiple even though the current return on equity is negative at 97.32% and the company is still unprofitable.

Compared with both the broader US Biotechs industry, at 2.7x P/B, and its closer peer group, at 5.1x P/B, Cogent’s 29.2x stands out as very expensive on this metric. Anyone looking at the stock is effectively paying a large premium relative to sector norms for that growth profile and pipeline potential to play out.

Result: Price-to-book of 29.2x (OVERVALUED)

However, this story still hinges on successful trial outcomes and further FDA decisions, so any clinical setback or regulatory delay could quickly challenge the current optimism.

Build Your Own Cogent Biosciences Narrative

If you look at these numbers and reach a different conclusion, or simply want to test your own view against the data, you can build a tailored thesis in just a few minutes with Do it your way.

A great starting point for your Cogent Biosciences research is our analysis highlighting 1 key reward and 4 important warning signs that could impact your investment decision.

Looking for more investment ideas?

If Cogent has sharpened your focus, do not stop here. Widening your search can help you spot opportunities you would otherwise miss.

• Chase potential mispricings by scanning these 869 undervalued stocks based on cash flows that line up with your view on quality and future prospects.
• Tap into long term technology shifts by tracking these 25 AI penny stocks that are building real businesses around artificial intelligence.
• Target income focused opportunities by shortlisting these 13 dividend stocks with yields > 3% that could complement a growth heavy portfolio.

This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.